To evaluate the in vivo impact of ibrutinib on platelet aggregation, we performed LTA testing in subjects receiving stable ibrutinib therapy. Human Ethics Research Committee approved platelet studies ...
Proteolytic degradation products of fibrinogen, produced as a result of excessive fibrinolysis, have been demonstrated in the blood of cirrhotic patients. 7,8 Such degradation products, when formed in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback